Seelos Therapeutics Inc (SEEL)

[MasterMerlins]

Markkind,

I think your right.. Regarding you Statement .. Especially the part where you say.. Absent any News..!

The problem arises with people that try and misinform others in order to manipulate..

You have said it well.. The Newly Registered Shares..! That is what Yesterdays filing was about.. It is not A Secondary Filing, like Slow posted.. We knew before hand that they were going to Register the shares that these Companies were going to get..!

Heck.. It seems like even Apricus was forced to issue a P.R. regarding this.. As the Manipulation and misinformation is rampant..

http://finance.yahoo.com/news/apricus-biosciences-issues-statement-regarding-160516212.html

SAN DIEGO, July 17, 2012 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. ("Apricus Bio") (APRI) (www.apricusbio.com) today issued the following statement regarding the registration of 3,706,397 shares of the Company's common stock on U.S. Securities and Exchange Commission resale Form S-3, filed yesterday, July 16, 2012:

"The shares Apricus Bio has registered in a resale S-3 filing relate to the Stock Contribution Agreement by and among Finesco, Scomedica and related parties, and Apricus Biosciences, Inc, as well as shares issued to PediatRx Inc. pursuant to the Termination Agreement by and between Apricus Biosciences, Inc. and PediatRx Inc. None of the shares relate to fund raising or financing activities.

"As the Company announced on July 13, Apricus Bio has closed an agreement to own Finesco, the French parent and holding company of Scomedica, a leading French healthcare contract sales and marketing organization, by way of a share contribution. Finesco and Scomedica will operate as wholly-owned subsidiaries of Apricus Bio. Finesco's existing shareholders contributed to Apricus Bio 100% of the outstanding common stock of Finesco in exchange for 2,592,592 newly issued shares of Apricus Bio common stock valued at EURO7 million ($8.8 million USD). Additional, 740,671 newly issued shares worth approximately EURO1.8 ($2.3 million USD) are due in the first quarter of 2013 if Scomedica achieves certain revenue milestones during 2012.

"As announced at the signing of the agreement, bringing Finesco and Scomedica into the Apricus Bio family of companies enables the Company to bring its own drugs and additional partnered drugs to the key French market to build a strong pipeline in this country, and is an important component of the Company's long-term commercial strategy in Europe."


And by the way.. Usually.. Every Press Release has Dr. Damaj Quoted somewhere in there.. Notice how there is no Quote from Dr. Damaj Today..!

Two Reasons come to mind..

1- Dr. Damaj is in Canada Today meeting with Health Canada..
2- And this was not a Prepared Statement.. It's in response to .. Either Many Investors Calls or all the Misinformation and Manipulation that is happening..